Supernus Pharmaceuticals Inc (SUPN)

Return on assets (ROA)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	73,865	59,712	5,239	-15,508	1,316	25,622	43,347	52,043	60,711	37,672	57,485	73,346	53,424	81,750	100,185	111,126	126,950	129,311	118,174	116,234
Total assets	US$ in thousands	1,368,070	1,342,700	1,315,830	1,304,090	1,277,670	1,285,160	1,293,100	1,791,810	1,702,510	1,693,130	1,694,970	1,639,520	1,689,150	1,555,040	1,573,060	1,507,440	1,504,100	1,510,020	1,491,020	1,189,870
ROA		5.40%	4.45%	0.40%	-1.19%	0.10%	1.99%	3.35%	2.90%	3.57%	2.22%	3.39%	4.47%	3.16%	5.26%	6.37%	7.37%	8.44%	8.56%	7.93%	9.77%

December 31, 2024 calculation

ROA = Net income (ttm) ÷ Total assets
= $73,865K ÷ $1,368,070K
= 5.40%

Supernus Pharmaceuticals Inc's return on assets (ROA) has shown a gradual decline over the period from March 31, 2020, to December 31, 2024. The ROA figures started at a healthy 9.77% in March 2020 but have since fluctuated, indicating a decrease in the company's efficiency in generating profits from its assets.

The ROA figures decreased to 0.10% in December 2023, hitting a low point. This suggests that the company was less effective in utilizing its assets to generate profits during that time. However, there has been a slight improvement in the following quarters, with the ROA reaching 5.40% by December 2024.

Overall, the declining trend in ROA indicates that Supernus Pharmaceuticals Inc may need to focus on improving asset utilization and operational efficiency to enhance its profitability in the future.